Inspira Technologies announced a non‑binding term sheet for a two‑part transaction that will see the company acquire a development‑ready liquid‑biopsy diagnostics business and receive a concurrent $15 million equity investment at a pre‑money valuation of $180 million, a premium to its current market capitalization of roughly $32.5 million.
The target platform isolates and characterizes circulating tumor cells from standard blood samples and has demonstrated high concordance with traditional tissue biopsies in early clinical studies. The acquisition positions Inspira to enter the projected $58 billion liquid‑biopsy market over the next decade, with plans to pursue FDA clearance via the 510(k) pathway and an existing reimbursement code for its intended clinical use.
The $15 million investment will be used primarily to fund ongoing development of Inspira’s respiratory and blood‑monitoring technologies, with $12 million earmarked for continued operations and product development. The transaction preserves the economic upside of Inspira’s existing platforms for current shareholders through a shareholder protection framework that includes contingent value rights.
CEO Dagi Ben‑Noon emphasized that the deal expands Inspira’s portfolio into a high‑growth diagnostics market while maintaining focus on its core life‑support technologies. The acquisition represents a significant strategic shift, transforming Inspira into a dual‑platform MedTech company that can leverage its existing manufacturing and regulatory experience to accelerate commercialization of the liquid‑biopsy platform.
The announcement was well received by investors, reflecting confidence in the company’s ability to diversify revenue streams and tap into a rapidly expanding market. The equity investment provides much‑needed capital to offset Inspira’s ongoing cash burn and supports the company’s long‑term growth strategy.
Ben‑Noon noted that the transaction is structured to protect existing shareholders, preserving their full economic upside to all future realizations of value from the company’s respiratory and blood‑monitoring technologies while providing exposure to the new diagnostics opportunity. The company remains focused on achieving FDA clearance and building a robust reimbursement strategy to support commercial adoption.
The strategic investor’s identity has not yet been disclosed, but the investment signals strong confidence in Inspira’s technology and execution capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.